Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.

[1]  Karsten Mäder,et al.  Solid lipid nanoparticles , 2012 .

[2]  Jiyue Cao,et al.  Tilmicosin enteric granules and premix to pigs: Antimicrobial susceptibility testing and comparative pharmacokinetics , 2019, Journal of veterinary pharmacology and therapeutics.

[3]  S. Talegaonkar,et al.  Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability , 2019, AAPS PharmSciTech.

[4]  Wenzhong Zhou,et al.  Evaluation of the antibacterial activity of tilmicosin-SLN against Streptococcus agalactiae: in vitro and in vivo studies , 2018, International journal of nanomedicine.

[5]  L. Junfeng,et al.  Tilmicosin‐ and florfenicol‐loaded hydrogenated castor oil‐solid lipid nanoparticles to pigs: Combined antibacterial activities and pharmacokinetics , 2018, Journal of veterinary pharmacology and therapeutics.

[6]  L. Junfeng,et al.  Preparation, characterization, and pharmacokinetics of tilmicosin‐ and florfenicol‐loaded hydrogenated castor oil‐solid lipid nanoparticles , 2017, Journal of veterinary pharmacology and therapeutics.

[7]  Bing Li,et al.  Determination of antibacterial agent tilmicosin in pig plasma by LC/MS/MS and its application to pharmacokinetics. , 2017, Biomedical chromatography : BMC.

[8]  F. Atyabi,et al.  Preparation and Characterization of Three Tilmicosin-loaded Lipid Nanoparticles: Physicochemical Properties and in-vitro Antibacterial Activities , 2016, Iranian journal of pharmaceutical research : IJPR.

[9]  S. Baboota,et al.  Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  C. Ghelardini,et al.  Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  A. Neves,et al.  Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery. , 2016, Journal of colloid and interface science.

[12]  V. Préat,et al.  Nanostructured lipid carriers: Promising drug delivery systems for future clinics. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[13]  S. Baboota,et al.  Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration , 2015, Drug delivery.

[14]  S. Eğrilmez,et al.  Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  Ting Wang,et al.  Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes , 2014, International journal of nanomedicine.

[16]  In-Soo Yoon,et al.  Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery , 2013, Journal of Pharmaceutical Investigation.

[17]  A. Neves,et al.  Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability , 2013, International journal of nanomedicine.

[18]  R. Tan,et al.  Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  Ruth Duncan,et al.  Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. , 2012, Molecular pharmaceutics.

[20]  Y. Wang,et al.  Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. , 2012, Veterinary journal.

[21]  Wenzhong Zhou,et al.  Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles , 2011, Particle and Fibre Toxicology.

[22]  E. Jäger,et al.  Formulation of lipid core nanocapsules , 2011 .

[23]  J. Benoit,et al.  Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  M. Rafiq,et al.  In vitro and in vivo evaluation of two sustained release formulations of diltiazem HCl , 2010 .

[25]  J. Benoit,et al.  The gastrointestinal stability of lipid nanocapsules. , 2009, International journal of pharmaceutics.

[26]  S. Xie,et al.  Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. , 2009, Journal of veterinary pharmacology and therapeutics.

[27]  Heike Bunjes,et al.  Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. , 2007, Advanced drug delivery reviews.

[28]  Zhinan Xu,et al.  STUDY ON THE EXTRACTION EQUILIBRIUM OF TILMICOSIN BETWEEN THE AQUEOUS AND BUTYL ACETATE PHASES , 2006 .

[29]  S. Zeng,et al.  Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. , 2005, Colloids and surfaces. B, Biointerfaces.

[30]  R. Yokel,et al.  The chemical species of aluminum influences its paracellular flux across and uptake into Caco-2 cells, a model of gastrointestinal absorption. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  W Mehnert,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  P. Blackall,et al.  In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. , 1995, Australian veterinary journal.

[34]  H. Tomoda,et al.  Temperature effect on endocytosis and exocytosis by rabbit alveolar macrophages. , 1989, The Journal of biological chemistry.

[35]  E. E. Ose.  In vitro antibacterial properties of EL-870, a new semi-synthetic macrolide antibiotic. , 1987, The Journal of antibiotics.

[36]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .